ARID1A and breast cancer: In contrast, ARID1A (TCGA=2%, BC=13%), NOTCH2 (TCGA=1%, BC=18%) and USH2A (TCGA=5%, BC=26%) mutations were detected at much higher rates in our samples than in those reported by TCGA.